Orticumab - Abcentra
Alternative Names: 2D03; Anti-oxLDL; BI-204; MLDL-1278A; RG-7418Latest Information Update: 03 Jun 2024
Price :
$50 *
At a glance
- Originator BioInvent International
- Developer Abcentra; BioInvent International; Genentech
- Class Anti-inflammatories; Antibodies; Antihyperlipidaemics; Antipsoriatics; Cardiovascular therapies; Monoclonal antibodies
- Mechanism of Action Immunomodulators; LDL receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Psoriasis
- No development reported Aortic valve stenosis; Atherosclerosis
Most Recent Events
- 06 Apr 2024 Efficacy data from phase II trial in Psoriasis presented at 73rd Annual Scientific Session of the American College of Cardiology (ACC-2024)
- 28 Jul 2023 No recent reports of development identified for preclinical development in Aortic-valve-stenosis in USA (Parenteral)
- 28 Feb 2022 No recent reports of development identified for clinical-Phase-Unknown development in Atherosclerosis in USA (Parenteral)